000282508 001__ 282508
000282508 005__ 20240229155043.0
000282508 0247_ $$2doi$$a10.1177/17588359231195199
000282508 0247_ $$2pmid$$apmid:37667779
000282508 0247_ $$2pmc$$apmc:PMC10475237
000282508 0247_ $$2ISSN$$a1758-8340
000282508 0247_ $$2ISSN$$a1758-8359
000282508 0247_ $$2altmetric$$aaltmetric:153820175
000282508 037__ $$aDKFZ-2023-01797
000282508 041__ $$aEnglish
000282508 082__ $$a610
000282508 1001_ $$0P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aWankhede, Durgesh$$b0$$eFirst author$$udkfz
000282508 245__ $$aThe prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis.
000282508 260__ $$aThousand Oaks, Calif.$$bSage$$c2023
000282508 3367_ $$2DRIVER$$aarticle
000282508 3367_ $$2DataCite$$aOutput Types/Journal article
000282508 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1695295331_13060
000282508 3367_ $$2BibTeX$$aARTICLE
000282508 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282508 3367_ $$00$$2EndNote$$aJournal Article
000282508 500__ $$a#EA:C070#
000282508 520__ $$aTumor mutation burden (TMB) has been validated as a predictive biomarker for immunotherapy response and survival in numerous cancer types. Limited data is available on the inherent prognostic role of TMB in early-stage tumors.To evaluate the prognostic role of TMB in early-stage, resected non-small cell lung cancer (NSCLC).Systematic review and meta-analysis of pertinent prospective and retrospective studies.Publication search was performed in PubMed, Embase, Cochrane Library, and Web of Science databases. Based on the level of heterogeneity, a random- or fixed-effects model was used to calculate pooled effects of hazard ratio (HR) for overall survival (OS) and disease-free survival (DFS). The source of heterogeneity was investigated using sensitivity analysis, subgroup analysis, and publication bias assessment.Ten studies comprising 2520 patients were included in this analysis. There was no statistically significant difference in OS (HR, 1.18, 95% CI, 0.70, 1.33; p 0.53, I2 = 80%; phet < 0.0001) and DFS (HR, 1.18, 95% CI, 0.91, 1.52; p = 0.53, I2 = 75%; phet = 0.0001) between the high-TMB and low-TMB group. Subgroup analyses indicated that East Asian ethnicity, and TMB detected using whole exome sequencing, and studies with <100 patients had poor DFS in the high-TMB group.The inherent prognostic role of TMB is limited in early-stage NSCLC. Ethnic differences in mutation burden must be considered while designing future trials on neoadjuvant immunotherapy. Further research in the harmonization and standardization of panel-based TMB is essential for its widespread clinical utility.Registration: CRD42023392846.
000282508 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000282508 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282508 650_7 $$2Other$$adisease-free survival
000282508 650_7 $$2Other$$ameta-analysis
000282508 650_7 $$2Other$$anon-small cell lung cancer
000282508 650_7 $$2Other$$aoverall survival
000282508 650_7 $$2Other$$atumor mutation burden
000282508 7001_ $$aGrover, Sandeep$$b1
000282508 7001_ $$aHofman, Paul$$b2
000282508 773__ $$0PERI:(DE-600)2503443-1$$a10.1177/17588359231195199$$gVol. 15, p. 17588359231195199$$p17588359231195199$$tTherapeutic advances in medical oncology$$v15$$x1758-8340$$y2023
000282508 909CO $$ooai:inrepo02.dkfz.de:282508$$pVDB
000282508 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000282508 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000282508 9141_ $$y2023
000282508 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-06-02T13:48:07Z
000282508 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-06-02T13:48:07Z
000282508 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000282508 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000282508 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-11
000282508 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-11
000282508 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-26$$wger
000282508 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTHER ADV MED ONCOL : 2022$$d2023-08-26
000282508 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000282508 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000282508 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000282508 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-06-02T13:48:07Z
000282508 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000282508 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000282508 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000282508 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000282508 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000282508 980__ $$ajournal
000282508 980__ $$aVDB
000282508 980__ $$aI:(DE-He78)C070-20160331
000282508 980__ $$aUNRESTRICTED